Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | An update on AMG 330: can BiTEs be as successful in AML as ALL?

Marion Subklewe • 2 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia AMG 330 Antibodies

After several successes in the acute lymphoblastic leukemia (ALL) setting, bi-specific T-cell engager (BiTE) therapies are now being tested in acute myeloid leukemia (AML). Here, Marion Subklewe, MD, of the LMU Hospital Munich, Munich, Germany, discusses the latest data presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA on a Phase I trial using AMG-330, a CD33/CD3 BiTE.

More from Marion Subklewe

1:43
CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment
Marion Subklewe • 9 Dec 2023
1:04
MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial
Marion Subklewe • 9 Dec 2023
1:42
Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML
Marion Subklewe • 9 Dec 2023
2:33
Novel immunotherapies in AML and insights into the future of the treatment landscape
Marion Subklewe • 9 Dec 2023

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals